Alpa Laboratories share news and announcements
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Last close ₹49.29down ₹2.17 (4.22%)BSE ₹49.47
Share price at the NSE close on 23 Oct 2026. Previous close ₹51.46.
52-week range of traded prices to 23 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹104 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 Jul 2026
- 0.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 23 Jul 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,17675.0% delivered
Alpa Laboratories share news and announcements
363 announcements, routine notices left out, newest first. Page 2 of 8.
Feb 2025
7 Feb · Disclosure of material issue
Nov 2024
14 Nov · Board meeting
Oct 2024
Sep 2024
28 Sep · Meeting
Aug 2024
31 Aug · Board meeting
14 Aug · Updates
13 Aug · Board meeting
May 2024
Mar 2024
18 Mar · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
Feb 2024
13 Feb · Board meeting
13 Feb · Board meeting
Nov 2023
Oct 2023
Sep 2023
11 Sep · Updates
Aug 2023
28 Aug · Updates
28 Aug · Board meeting
Jul 2023
Jun 2023
8 Jun · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results not signed by authorized signatory/ies The response of the Company is awaited.
May 2023
Mar 2023
9 Mar · Legal
Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Feb 2023
Jan 2023
21 Jan · Legal
The exchange asked on 20 Jan 2023
Nov 2022
24 Nov · Related Party Transaction